A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07227402
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belzutifan — DRUG
    Administered orally QD
  • Zanzalintinib — DRUG
    Administered orally QD
  • Cabozantinib — DRUG
    Administered orally QD

Study Details

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

Key Dates

First listed
Nov 12, 2025
Start date
Nov 26, 2025
Status verified
Jul 2026
Primary completion
Feb 27, 2032
Completion
Feb 27, 2032

Study Design

Enrollment
904 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Belzutifan plus Zanzalintinib
    Participants will receive belzutifan orally once daily (QD) PLUS zanzalintinib orally QD until one of the reasons for discontinuation of study intervention are met.
  • Active Comparator: Cabozantinib
    Participants will receive cabozantinib orally QD until one of the reasons for discontinuation of study intervention are met.

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: Up to approximately 73 months ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Alaska Oncology and Hematology ( Site 0133)AnchorageAlaska99508
Study Coordinator
907-257-9851
Providence Medical Foundation ( Site 0141)FullertonCalifornia92835
Study Coordinator
714-446-5900
Cedars-Sinai Medical Center ( Site 0112)Los AngelesCalifornia90048
Study Coordinator
310-423-3227
New England Cancer Specialists ( Site 0132)WestbrookMaine04092
Study Coordinator
207-303-3300
Greater Baltimore Medical Center ( Site 0145)BaltimoreMaryland21204
Study Coordinator
443-849-8136
Metro-Minnesota Community Clinical Oncology ( Site 0144)Saint Louis ParkMinnesota55426
Study Coordinator
952-993-1555
Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131)OmahaNebraska68130-2042
Study Coordinator
402-691-6971
Carolina Oncology Specialists, PA ( Site 9002)CharlotteNorth Carolina28207
Study Coordinator
704-342-1900
Thompson Cancer Survival Center ( Site 0125)KnoxvilleTennessee37916
Study Coordinator
865-331-1678

Find similar trials in Anchorage, AK

Nationwide
Kidney cancer trialsOncology trialsUrology trials
By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Alaska Oncology and Hematology· Anchorage, AKProvidence Medical Foundation· Fullerton, CACedars-Sinai Medical Center· Los Angeles, CANew England Cancer Specialists· Westbrook, MEGreater Baltimore Medical Center· Baltimore, MDMetro-Minnesota Community Clinical Oncology· Saint Louis Park, MN

Related Studies